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The hairy leukoplakia lesion (HLP) is a unique example of a permissive infection with Epstein–Barr virus (EBV) in the tongue
epithelium. HLP contains abundant replicating viral DNA and may be coinfected with multiple EBV strains. In this study,
characterization of viral gene transcription within HLP biopsy specimens revealed that several genes, usually expressed in
latently infected lymphocytes, are also transcribed in the HLP lesion. The BamHI W and C promoters, (Wp and Cp) are
consistently active in the HLP lesion, resulting in transcription and processing of mRNAs that encode the Epstein–Barr
nuclear antigens (EBNAs) EBNA-LP, EBNA1, EBNA2, EBNA3B, and EBNA3C. The EBNA2 protein has been shown to activate
expression of the EBV receptor, CD21. In HLP, CD21 transcription is also detected, usually in samples that contain transcripts
for EBNA2. Transcripts encoding the LMP1 gene, the LMP2 gene, and rightward transcripts from the BamHI A fragment of
the EBV genome are also detected in HLP. These gene products are invariably expressed in latently infected lymphocytes.
This pattern of transcription suggests that genes characteristic of latent infection are also expressed in HLP. The activation
of Wp and expression of EBNA2 and CD21 may contribute to the unique ability of the HLP lesion to permit superinfection and
viral replication of multiple EBV strains. © 1998 Academic Press
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INTRODUCTION
Epstein–Barr virus is a ubiquitous human herpesvirus
that infects greater than 90% of the population world-
wide. Although lymphoid infection is well characterized,
the virus has a dual tropism for lymphocytes and epithe-
lial cells (Rickinson et al., 1975; Sixbey et al., 1984; Kieff,
1996). In epithelial cells, pathologies representing both
latent and productive infections have been detected in
vivo. In nasopharyngeal carcinoma (NPC), the latent vi-
rus persists within the epithelium of the nasopharynx,
while the hairy leukoplakia lesion (HLP), an oral mucosal
lesion primarily associated with immunosuppression, is
characterized by productive EBV infection within the
squamous epithelial cells of the lateral tongue border
(Raab-Traub et al., 1983; Greenspan et al., 1985; Raab-
Traub and Flynn, 1986; Gilligan et al., 1990). Replicating
EBV is also detected in normal oropharyngeal epithelial
cells shed into saliva during terminal stages of differen-
tiation (Lemon et al., 1978; Sixbey et al., 1984). Two major
strains of EBV have been described, type 1 and type 2,
that have considerable sequence divergence in the
genes that encode for Epstein–Barr nuclear proteins
(EBNA) 2, 3A, 3B, and 3C in latently infected cells (re-
viewed in Kieff, 1996). HLP lesions are frequently coin-
fected with Type 1 and Type 2 and are infected with
multiple strains distinguished by sequence variation
within the latent membrane protein 1 (LMP1) gene (Wall-
ing et al. 1992, 1994; Miller et al., 1994; Palefsky et al.,
1996).
Multiple patterns of gene expression distinguish dis-
tinct states of latent EBV infection (Kerr et al., 1992). The
best characterized state of infection is of B cell lympho-
blastoid lines (LCLs) that have been immortalized by EBV
infection in vitro. This type of latency (type III) has also
been identified in immunoblastic B cell lymphomas of
immunosuppressed individuals and in patients with in-
fectious mononucleosis (Thomas et al., 1990; Hamilton-
Dutoit et al., 1993). Type III latency is marked by expres-
sion of the EBNAs (EBNA1, -2, -3A, -3B, -3C, and -LP),
latent membrane proteins (LMP1, -2A, and -2B), EBERs
(small nonpolyadenylated RNAs), and transcripts from
the BamHI A region. A distinct form of latency (type II)
occurs in NPC and Hodgkin’s disease (HD) with expres-
sion of EBNA1, LMP1, LMP2, EBERs, and BamHI A tran-
scripts (Raab-Traub, 1992; Deacon et al., 1993). Type I
latency, the most restricted pattern of expression, limited
to EBNA1 and the EBERs, is found in Burkitt’s lymphoma
(BL) (Rowe et al., 1987). A fourth type of latency has been
identified in B lymphocytes in healthy carriers with ex-
pression of EBNA1, LMP2, and EBER1 RNA (Qu and
Rowe, 1992; Tierney et al., 1994; Chen et al., 1995). These
patterns of latency can be distinguished in part by the
promoter usage for the six nuclear antigens. Transcrip-
tion for all the EBNAs can initiate from within BamHI W or
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C at either the BamHI Wp or Cp viral promoters in latency
III, while in latency I and II only EBNA1 is expressed and
the mRNA initiates at a promoter within BamHI Q (Qp)
(Sample et al., 1986, 1991; Speck et al., 1986; Bodescot et
al., 1987; Schaefer et al., 1995; Nonkwelo et al., 1996). Wp
and Cp are autoregulated by their gene products, EBNA1,
EBNA2, and EBNA-LP (Sung et al., 1991; Woisetschlaeger
et al., 1991; Puglielli et al., 1996; Yoo et al., 1997). The
EBNA2 and EBNA3 nuclear antigens also regulate ex-
pression of cellular genes, including CD21, the primary
EBV receptor (Wang et al., 1987a; Cooper et al., 1990;
Cordier et al., 1990).
Permissive infection has been largely studied in B cell
lines treated with chemical agents or, in the case of the
latently infected Burkitt lymphoma line Akata, through
crosslinking of surface immunoglobulin (Blazar et al.,
1980; Takada, 1984). Like other herpesviruses, EBV ex-
presses many genes in a temporal cascade during per-
missive infection with immediate early, early, and late
gene products. Upon activation of the lytic cycle in la-
tently infected cells, a novel lytic promoter within BamHI
F (Fp), located adjacent to Qp, is activated (Sample et al.,
1991; Schaefer et al., 1995). During permissive infection,
the EBNA1 mRNA is transcribed from Fp and contains
exons from BamHI Q, U, and K.
In contrast to induced LCLs, which contain both la-
tently and permissively infected cells, HLP is thought to
represent a purely permissive infection of epithelial cells.
The replicative antigens are readily detected in HLP, and
the lesion contains abundant linear virion DNA, evi-
denced by a ladder array of restriction enzyme fragments
unique to productive infection (Gilligan et al., 1990; Lau et
al., 1993). It has previously been shown that EBERs, a
hallmark of latent infection, are not expressed in HLP
(Gilligan et al., 1990). Other gene products characteristic
of latent infection, however, have been detected within
HLP. EBNA2 and LMP1 transcription has been detected
in HLP, and weak EBNA staining has been observed in
the middle to upper stratum spinosum of the lesion
(Gilligan et al., 1990; Niedobitek et al., 1991; Thomas et
al., 1991; Walling et al., 1994).
These latent proteins have important effects on cellu-
lar gene expression and growth control and could be
responsible for some of the unique aspects of the HLP
lesion. Unlike other permissive herpesvirus infectious
lesions, HLP is marked by thickening of the epithelium
with evidence of cellular proliferation. In this study, to
further characterize EBV infection in HLP, promoter us-
age and transcription of specific latent genes within HLP
have been analyzed using reverse-transcriptase-based
polymerase chain reaction (RT-PCR). Correctly spliced
transcripts for most of the EBV latent genes were de-
tected with the EBNA transcripts originating from Wp, Cp,
and Fp. Thus, EBV infection in HLP has a combined
pattern of transcription with usage of lytic and latent
promoters.
RESULTS
EBNA transcription in HLP
To determine the relative abundance of specific EBV
transcripts, all cDNA preparations were synthesized
from 10 mg of RNA, and identical aliquots of cDNA were
used for each PCR amplification with the different primer
sets. After amplification, separation on agarose gels, and
transfer to nitrocellulose, the products were hybridized to
equal amounts of end-labeled oligonucleotide probes
and exposed to film for equivalent amounts of time. This
method, although not as quantitative as competitive PCR,
does enable some comparison of relative abundance of
amplified products.
In latently infected B cells, EBNA2 is essential for
transformation and the regulation of many latent viral
genes and cellular genes. The EBNA2 gene itself differs
extensively between the two major EBV types. In HLP,
considerable genomic recombination has been detected
within the EBNA2 gene, and transcription of EBNA2 from
both the wild-type and defective genomes has been
detected in HLP (Walling et al., 1994). To identify EBNA2
transcripts in the HLP samples, a primer pair, 59Y2 to
39YH, was used to identify the EBNA2 mRNA, which is
spliced from sequences within BamHI Y to the EBNA2
open reading frame (ORF) BamHI H (Table 1). The cor-
rectly sized 209-bp product was easily detected after a
single set of amplifications in 12/14 HLP specimens
tested, as was a 596-bp product representing unpro-
cessed mRNA and contaminating genomic DNA (Fig. 1,
Table 2). The 209-bp product was detected in samples
HL10 and HL15 after longer exposure of the autoradio-
graph.
As the EBNA2 and EBNA3 genes are transcribed from
alternately spliced mRNAs that initiate from the same
promoter, expression of EBNA3 was also evaluated. The
EBNA 3 family of transcripts (EBNA 3A, 3B, 3C) are the
least abundant EBNA mRNAs in latently infected lympho-
cytes. Interestingly, EBNA3B was detected in 3/6 HLP
specimens while EBNA3C was detected in 4/6 samples
after a single round of amplification (Table 2). EBNA3A
transcription was not evaluated.
EBNA2, EBNA3A, EBNA3B, EBNA3C, and EBNA-LP mR-
NAs may initiate from either Wp or Cp (Woisetschlaeger et
al., 1990). After initial infection, Wp is activated in the ab-
sence of expression of other viral factors (Wang et al.,
1987b). Subsequent expression of EBNA2 and EBNA-LP is
thought to activate Cp, with EBNA-LP augmenting EBNA2
transactivation (Harada and Kieff, 1997; Nitsche et al., 1997).
Depending on the splice acceptor site, both the Wp- and
Cp-initiated transcripts containing the W1 and W2 exons
potentially encode EBNA-LP (Sample et al., 1986; Wang et
al., 1987b; Rogers et al., 1990). Interestingly, in 13/13 HLP
lesions, Wp-initiated transcripts containing the W1 and W2
exons were detected after a single round of amplification.
Cp usage, with transcription to exons C1/C2/W1/W2 within
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BamHI C and W, respectively, was detected in 7 of 13 HLPs
after a single round of amplification (Fig. 1, Table 2). Al-
though the Wp and Cp blots were hybridized at the same
time to the same probe, the hybridization signals for the
Cp-initiated transcripts were considerably weaker than
those detected for Wp-initiated transcription when the au-
toradiographs were exposed for equal amounts of time as
shown in Fig. 1. The 196-bp PCR product representing the
correctly spliced Wp-initiated mRNAs was readily detected
and distinguished from products representing unspliced
RNA or DNA on shorter exposures of the autoradiograph.
However, the equivalent exposure time could not detect
Cp-initiated transcripts (data not shown). This suggests that
Wp-initiated transcription is the predominant form in HLP.
Wp transcription and EBNA2 transcription correlated in
10/12 samples (Fig. 1, Table 2). Hybridization with a 32P-
labeled BamHI W1 fragment probe on Northern blots de-
tected transcripts of approximately 3.0 and 3.7 kb in 2/3
HLP specimens (data not shown). These mRNAs could
correspond to EBNA2 and EBNA1 transcripts that have
been identified in lymphocytes.
In reconstruction experiments to determine the rela-
tive sensitivity of amplification of specific viral promoter
initiated transcripts by RT-PCR, cell mixtures containing a
TABLE 1
Oligonucleotides Used for RT-PCR Analysisa
Target transcript Primer specificity Primer sequence B95-8 Coordinatesb
Wp-initiated mRNAs W159 primer AGACCGAAGTGAAGGCCCTG 14562–14581
Cp-initiated mRNAs W0 59 primer TCAGAGCGCCAGGAGTCCAC 14385–14404
C1 59 primer AAGACCTACGCCCTCTCCATT 11431–11450
Common primer W2 39 primer CCTCCTCTTCTTGCTGGACG 14809–14791
Common probe W2 probe TTGGCCCCTCTGGTAGGAC 14761–14741
EBNA1:Fp/Qp initiated 59 primer GGTGGATAGAGAGGAGGGGGGTCCGGAGG 62239–62267
EBNA1:Cp/Wp/Fp/Qp initiated U probe CCGCGGCGGTGAATCTGCGTC 67630–67610
U59 primer AGTAGTCTCAGGGCATC 67544–67563
k59 primer TGTGAATCATGTCTG 107986–108001
K probe ATTTCCAGGTCCTGTACCTGGCCCCCCT 10797–10770
EBNA2 K39 primer TCTTCTTTTGAGGTCCAC 108051–108032
Y2 59 primer GCGCCAATCTGTCTACATAG 47904–47959
YH probe CGGGTGCTTAGAAGGGTTGTT 48473–48454
YH 39primer CCCCATGTAACGCAAGATAG 48534–48515
EBNA3B 3B 59 primer TGGTGGTGACGATCCCTTGGATG 95597–95617
3B probe GTCCGATTG/CAACATGGAA 95690–95680/95710–95704
3B 39 primer CTTCGATGTTCAGGTTTTGC 95845-95826
EBNA3C 3C 59 primer ATACCGCAAGGAATAT 98682-98702
3C probe GGTGCGATTGCTTGACAGCCC 98730–98720/98815–98805
3C39 primer GTGTGTTCTAACCCCACTATC 98859–98840
BARFO Exon VI 59 primer GTTTTGCGCCTGGAAGTTGT 157313–157331
Exon VI probe CGTGCCTCCAACGTCTTTGA 157394–157375
Exon VII 39 primer AGCTTTCCTTTCCGAGTCTG 159209–159190
LMP1 LMP1 59primer CACCCGAAGATGAACAGC 169,031–169,051
LMP1 39 primer CGCGACGGCCCCCTCGAGGAC 169,441–169,421
LMP1 59N primer ACAATTCCAAGGAACATGCC 169,070–169,091
LMP1 39N primer TCGTTATGAGTGACTGGA 169,351–169,334
LMP1 probe CCTTTGCTCTCATGCTTATAA 169,310–169,285
LMP2A LMP2 59primer AGGAACGTGAATCTAATGAAGA 166,703–166,723
LMP2 39 primer AAGTGACAACCGCAGTAAGCA 164–143
LMP2 59N primer GATTGCAACACGACGGGAATG 166,819–166,840
LMP2 39N primer TGTCACCGGTGTCAGCAGTT 142–121
LMP2 probe GAGTCATCCCGTGGAGTA 166,881–166,861
B-actin ACTIN 59 primer CCTTCCTGGGCATGGAGTCCT
ACTIN 39 primer GAAGATCAAGATCATTGCTCC
ACTIN probe ACATCCGCCAAAGACCTGTACGCCAACACAG
CD21 CD21 59 primer TTAATACGTCCTGCCAAGATGG
CD21 3 primer9 GGAGGTGGACACCCTATGAA
CD21 probe AGATAGAATCCTTGGTCACAT
CD45 CD45 5 9primer ATTTTGTGGCTTAAACTCTTGGCATTT
CD45 39 primer GTAGGGTTGAGTTTTGCATTGGCGGC
CD45 probe GTGTTTCATCAGTACAGACGCCTCA
a Oligonucleotide sequences used for polymerase chain reaction analysis of hairy leukoplakia for detection of EBV mRNA and cellular mRNA.
b Coordinates refer to genomic map of B95-8 virus.
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standard number of BJAB cells and 10-fold serial dilu-
tions of B95–8-infected cells were analyzed. It has been
previously shown that the Cp promoter is predominantly
used in B95–8 cells with some use of Wp and Fp (Woi-
setschlaeger et al., 1990). The W1/W2 PCR product is
common to both Cp- and Wp-initiated transcripts and
was detected at a dilution of 1:106. Amplifications of the
exon structure typical for Cp, C1/C2/W1/W2, detected
transcription at a dilution of 1:104. Amplifications of the
exon structure typical for Wp, W0/W1/W2, detected tran-
scription at a dilution of 1:102 (Fig. 1). These data are
identical to previous studies and comparison of Figs. 1B
and 1C indicates that B95–8 EBNA transcripts predomi-
nately originate from Cp (Tierney et al., 1994). In B95–8
cells, a subset of the EBNA transcripts apparently ini-
tiates from Wp or possibly initiates at Cp and contains an
exon that spans Wp. This is in contrast to HLP, where the
majority of transcription contains the Wp exon.
The EBNA1 protein has been detected in HLP and is
thought to be the only EBNA that continues to be made
FIG. 1. EBNA promoter usage in HLP. Detection of EBNA2 mRNA (A), Wp-initiated mRNA (B), and Cp-initiated mRNAs (C) in HLP by RT-PCR. Control
amplifications contain the EBV-positive B95–8 LCL (predominately latency 3, with 5% of cells in lytic cycle) and distilled (D) H2O. RT-PCR was carried
out with the relevant primer-probe combinations from Table 1, the products were hybridized overnight with 32P-labeled probes, and the autoradio-
graphs were exposed. 1, with reverse transcriptase; 2, without reverse transcriptase. (Longer exposure of the autoradiograph revealed EBNA2
amplification product in HL15.) Using the same primer–probe combinations, the sensitivity of RT-PCR was analyzed by detecting transcripts in RNA
preparations from mixed EBV-positive (B95–8) and EBV-negative (BJAB) lymphoid cell populations. The sensitivity for amplification of EBNA2 mRNA
(A) was at 1:104. Wp-initiated mRNA (B) was at 1:104. Cp-initiated mRNA (C) was at 1:104. Adjacent cartoons depict the exon structure of the transcripts.
Arrows show placement of 59 and 39 PCR primers. Filled boxes show region of oligonucleotide probe. Sensitivity of detection of transcripts in
reconstruction experiments is shown.
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during lytic cycle progression in B cells (Heller et al.,
1982; Weigel et al., 1985Murray et al., 1996). In lympho-
cytes, the EBNA1 transcripts originate from Cp or Wp in
latency type III or from Qp in type I or type II latency (Kieff,
1996; Nonkwelo et al., 1996). EBNA1 transcripts initiate at
fourth promoter, Fp, during lytic infection (Schaefer et al.,
1995; Nonkwelo et al., 1996). As the Fp and Qp promoters
are adjacent to each other and all Fp transcripts read
through Qp, most studies have not distinguished these
two promoters. However, all previously described EBNA1
transcripts splice into the BamHI U exon and subse-
quently into the BamHI K open reading frame. As approx-
imately 5% of B95–8 cells are permissively infected, the
Fp/Qp to K PCR product representing Fp-initiated tran-
scription was detected after a single round of amplifica-
tion (Fig. 2). Akata cells are considered to represent type
I latency, and the Fp/Qp PCR product representing Qp
transcription in uninduced cells and Fp transcription in
induced cells was detected after a single round of am-
plification. However, Wp activity was also detected in
uninduced Akata cells, suggesting that some of the
Akata cells had drifted into type III latency, as previously
described for other type I BL cell lines (Table 2). In the
nude mouse passaged NPC, C15, which represents Type
II latency, only Fp/Qp activity was detected after a single
round of amplification (Fig. 2, Table 2).
Although Fp is thought to be the EBNA1 promoter used
during viral replication, Fp activity could not be detected in
4/4 HLP samples, amplifying from Fp/Qp to K, or after a
second set of amplifications that amplified an aliquot of the
Fp to K material with internal primers that amplified from the
U exon into K (Fig. 2, Table 2). Amplifications from W0 to K,
C1 to K, and U to K were also negative in the HLP samples
(Table 2). This negative result did not reflect the sensitivity
of the assay or the quality of the cDNA preparations, as
EBNA2, Wp, and Cp transcripts were amplified from these
same cDNAs and actin was readily amplified from all sam-
ples (Table 2, Fig. 2B). In the control amplifications in the
TABLE 2
Latency Associated
EBV mRNA EBNA1 EBNA-LP EBNA2 EBNA3B EBNA3C ACTIN
1st round of
amplification
F-
K
C
1-
K
W
0-
K
U
-K
W
0-
K
C
1-
K
F-
K
F-
K
C
1-
W
2
W
0-
W
2
Y2
-Y
H
B
E
R
F2
B
E
R
F3
2nd round of
amplification K-
K
K-
K
K-
K
U
-K
Controls
Akata, IgG X-link 1 2 1 1 2 1 1 1 1
Akata 1 1 1 1 1 1 1 1
C15 1 1 1 2 2 1 1 1
B95-8 1 1 1 1 1 1 1 1 1 1 1
Hairy leukoplakia
HL1 2 1
HL7 2 1 1 1 1 1
HL9 2 2 1 1 1
HL14 2 1 1 1 1
HL15 2 1 1 6 1
HL23 2 1 1 1 1
HL30 2 2 2 2 2 1
HL31 1 2 2 2 1 1 1
HL32 1 2 2 1 1 2 2 1
HL33 1 2 2 2 1 1 1 1 1
HL10 1 1 6 1
HL11 2 2 2 2 1 2 1
HL12 2 2 2 1
HL16 1 2 2 2 2 1
HL34 1 1 1 22 1 1 1
HL35 1 2 1 2 2 2 1 1
HL36 1 2 1 2 2 2 1 1 1
HL37 2 2 1 1
HL38 2 2 1
HL39 2 2 1 1 1
HL13 1 1 1 1
HL22 2 1 2 1
Note. Summary of EBNA transcription in HLP. 1, positive amplification; 1/-, amplification signal. Shaded area indicates detection after a second
round of amplification. Amplification of actin was included for all samples to control for mRNA integrity.
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mixed cell experiment, the amplification from U to K could
be detected at a 1:104 dilution (Fig. 2B). These data suggest
either that Fp/Qp is not active in HLP or that the mRNA
structure is different from that previously described and
lacks an exon from BamHI U.
To determine how EBNA1 is transcribed in HLP, am-
plifications were performed from Wp, Cp, and Fp/Qp into
K. Because product was not detected in the initial round
of PCR, a second set of amplifications within the EBNA1
ORF in BamHI K was performed. This second amplifica-
tion detected transcripts whether the initial amplification
was from Wp, Cp, or Fp. Transcription from Wp was
detected in 3/6 samples, Cp in 3/7, and Fp/Qp in 6/6
samples with approximately equal intensity (data not
shown; Table 2). It is known that EBNA1 is expressed in
HLP as it has been detected on immunoblots (Murray et
al., 1996). In this study EBNA1 could be detected by
immunohistochemistry in tissue from these same HLP
samples (data not shown). These data suggest that in
HLP Wp, Cp, or Fp/Qp can be used concurrently for
EBNA1 transcription or that perhaps an as yet unidenti-
fied promoter may be used. Concurrent usage of Wp and
Fp/Qp has been previously described in several human
round B cell lines (Taylor et al., 1994).
Membrane-associated viral antigens in HLP
The EBV oncogene and TNF receptor family member
LMP1 is required for B cell transformation and also
affects cellular growth, differentiation, and apoptosis
(Kaye et al., 1993; Fries et al., 1996; Miller et al., 1995,
1997). LMP1 transgenic mice develop hyperkeratotic le-
FIG. 2. EBNA transcription in HLP. (A) RT-PCR screening for the F/Q/U/K spliced form of EBNA1 mRNA in RNA preparations of HLP pseudoHLP
(Green et al., 1989), and HIV-negative tongue. Control amplifications contain the EBV-positive B95–8 LCL (predominately latency III, with 5% of
cells in lytic cycle), C15, a nude mouse passaged NPC xenograft (latency II), and distilled (D) H2O. RT-PCR was carried out with the relevant
primer–probe combination from Table 1, the products were hybridized overnight with 32P-labeled probes, and the autoradiographs were
exposed. 1, with reverse transcriptase; 2, without reverse transcriptase. Amplification of B-actin was included for all samples to control for
mRNA integrity. (B) Detection of U/K spliced transcripts by RT-PCR in RNA preparations from mixed EBV-positive and EBV-negative cell
populations. Control amplification contains DH2O.
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sions similar to the abundant keratin produced in HLP
(Wilson et al., 1990). LMP1 transcripts have been de-
tected on Northern blots in HLP samples (Gilligan et al.,
1990). In this study, LMP1 transcription required two sets
of RT-PCR amplification to be detected and was present
in 8/9 specimens shown (Figs. 3 and 4). PCR amplifica-
tion sensitivity in the mixed cell experiment was at a 1025
dilution.
LMP2 is a signaling molecule known to suppress the
switch from latent to lytic infection (Miller et al., 1994).
Like LMP1, LMP2 is consistently detected in latency II/III.
The LMP2 mRNA contains exons from both ends of the
linear genome and is encoded by transcripts that splice
across the terminal repeats, thus usually requiring epi-
somal genomic forms. Two forms of LMP2 mRNA,
LMP2A and LMP2B, exist that differ in the first exon.
Primer pairs that represent exon 1A from the right end of
the EBV genome and exon 2 from the left end of the EBV
genome detected LMP2A mRNA in HLP. As HLP has a
predominance of linear DNA, the detection of LMP2
transcripts in 5/6 HLP lesions was surprising (Fig. 3).
Detection of LMP2 transcription also required two
FIG. 3. Transcription of BamHI A, LMP1, and LMP2 in HLP. (A) Summary of RT-PCR screening for BamHI A, LMP1, and LMP2 mRNAs in HLP. 1,
transcripts detected; 2, transcript not detected. Shaded area indicates detection after a second round of amplification. (B) RT-PCR for LMP1, LMP2,
and BamHI A was carried out with the relevant primer–probe combination from Table 1, the products were hybridized overnight with 32P-labeled
probes, and the autoradiographs were exposed. 1, with reverse transcriptase; 2, without reverse transcriptase. Using the same primer–probe
combinations, the sensitivity of RT-PCR was analyzed by detecting transcripts in RNA preparations from mixed EBV-positive and EBV-negative cell
populations. Amplification sensitivity for LMP1 mRNA and LMP2 mRNA was at 1:105 dilutions and for BamHI A was at 1:104 dilutions.
59GENE EXPRESSION IN HLP
rounds of PCR amplification, suggesting that this mRNA
may be present at low level. Because EBV replication is
believed to occur via a rolling circle yielding multiple
concatamers, it is possible that the LMP2 transcripts in
HLP may be transcribed from these concatamers (Sato
et al., 1990).
The presence of BamHI A transcripts was examined
within HLP. This family of transcripts was originally iden-
tified in the epithelial malignancy, NPC (Hitt et al., 1989;
Gilligan et al., 1991). These highly spliced BamHIA RNAs
are 39 coterminal, with all the transcripts containing the
open reading frame BamHI A rightward frame 0 (BARFO)
(Sadler and Raab-Traub, 1995). The BamHI A RNAs have
been detected in all three types of latency (Brooks et al.,
1993). The primer combination specific for the splice
from exon VI to VII detected transcripts at 1024 dilutions
of infected cells in sensitivity experiments, and these
transcripts were detected in 8/10 HLPs (Fig. 3).
Cellular genes in HLP
In reconstruction experiments, the majority of amplifi-
cations were detected in at least 1 infected cell in 104
cells. To ensure that the transcripts detected were strictly
reflective of infected epithelial cells in HLP and not due
to lymphocyte infiltration, transcription of the lymphocyte
specific marker CD45 was analyzed (Fig. 4). After two
sets of PCR amplification with the CD45-specific primer
pair, a specific product was not detected in 4/4 HLPs
tested, although LMP1-specific transcription was easily
detected in cDNA prepared from these same HLP sam-
ples. CD45 transcription was readily detected in the
B95–8 lymphoid line but was not detected in the epithe-
lial NPC tumor, C15. CD45 transcripts could be detected
at a 1:105 dilution. These data confirm that the EBV
transcription detected in the HLP samples represents
infected epithelial cells and not infiltrating lymphocytes.
The EBNA2 protein has been shown to upregulate
expression of the EBV receptor, CD21 (Wang et al., 1990;
Larcher et al., 1995). CD21 transcription was detected in
6/10 HLP samples. In all the samples tested, both Wp
activity and EBNA2 transcription were detected (Fig. 5).
The PCR products from two different HLP specimens
were further amplified by asymmetric PCR and were
sequenced, confirming that the amplification repre-
sented authentic CD21. These data suggest the detection
of CD21 expression correlates with Wp activity and
EBNA2 expression.
DISCUSSION
Previous studies have shown that induction of viral
replication in lymphoid cell lines does not affect latent
gene expression (Hummel and Kieff, 1982; Weigel et al.,
1985). In this study, spliced mRNAs expressed in latent
infection were consistently detected in a largely permis-
sive in vivo infection. This may indicate a role for these
latent gene products during viral replication and in the
pathogenesis of HLP.
Several lines of evidence indicate that these tran-
scripts are present in the infected HLP cells and do not
represent latently infected lymphocytes trafficking
through HLP. Perhaps most significantly, in cDNA prep-
arations where the EBV LMP1 mRNA was readily de-
tected, mRNA for the lymphocyte specific marker, CD45,
could not be amplified. Second, viral gene expression in
HLP is distinct from that previously described in periph-
eral blood lymphocytes (PBL). Although EBNA2 expres-
sion is not detected in PBL, in HLP both rearranged and
deleted recombinant variants of EBNA2 are transcribed
and easily detectable by RT-PCR. Transcription of the
defective molecules, which are unique to HLP, reveals
that the transcription arises from the progeny DNA mol-
ecules produced during permissive infection (Walling
and Raab-Traub, 1994; Walling et al., 1994).
An additional unique aspect of EBV transcription in
HLP is the structure of the EBNA1 transcripts. In lym-
phoid lines and in PBL, the EBNA1 transcript contains an
exon from BamHI U. However, in HLP, transcripts con-
taining the BamHI U exon spliced to the EBNA1 ORF in
BamHI K could not be detected. Lack of the BamHI U
exon supports a previous suggestion that the U exon
splice donor site is suppressed during the lytic cycle
(Schaefer et al., 1995).
Finally, the promoter usage in HLP is quite distinct
from that described in PBL or in latently infected epithe-
lial cells. In lymphoid cell lines, Wp and Cp activity is
thought to be mutually exclusive and Fp is activated
during replication (Woisetschlaeger et al., 1989; Schaefer
et al., 1995; Puglielli et al., 1997). In the HLP lesions
studied here, all three promoters were active although
FIG. 4. Lack of CD45 mRNA detection in HLP. The lymphocyte-
specific marker, CD45, was not detected in 4/4 HLPs after two rounds
of RT-PCR amplification. RT-PCR was carried out with the relevant
primer–probe combination from Table 1, the products were hybridized
overnight with 32P-labled probes, and the autoradiographs were ex-
posed. 1, with reverse transcriptase. As a control, nested RT-PCR for
LMP1 was carried out in the same samples. Control amplifications
contain the EBV-positive B95–8 LCL, C15, and distilled (D) H2O.
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Wp transcription was more easily detected than Cp or
Fp. Cp activity has been shown to be downregulated by
the immediate early protein BZLF1 (Z) (Kenney et al.,
1989; Sinclair et al., 1992). As Z is consistently expressed
in HLP, it may modulate Cp function (Niedobitek et al.,
1991). A recent study of EBV infection in lymphocytes
revealed that virus binding to the EBV receptor, CD21,
stimulates the transcription factor NF-kB, which in turn
activates Wp (Sugano et al., 1997). The presence of
abundant transcription from Wp in HLP may reflect Wp
activation due to virus binding to CD21.
CD21 expression has been detected in epithelial cell
lines, in nude mouse passaged NPC xenografts, and in
the mid to upper stratum spinosum of the tongue (Billaud
et al., 1989; Thomas et al., 1991; Birkenbach et al., 1992).
Interestingly in HLP, CD21 was detected in the same
cells in which EBV DNA was detected [Corso B, 1989
#5032]. In this study, CD21 mRNA was detected in 60% of
FIG. 5. Transcription of CD21 in HLP. In HLP EBNA2 and CD21, the EBV receptor is transcribed within some of the same specimens. (A) RT-PCR
for EBNA2 and CD21 was carried out with the relevant primer-probe combination from Table 1, the products were hybridized overnight with 32P-labeled
probes, and the autoradiographs were exposed. 1, with reverse transcriptase; 2, without reverse transcriptase. EBNA2 transactivation of CD21 has
been described in lymphocytes. Two of four HLP samples in this representative panel contain both mRNAs. Control amplifications contain the
EBV-positive cell lines B95–8-LCL and Akata BL. (B) Summary of transcription of EBNA2, CD21, and Wp-initiated transcripts in 10 HLPs. 1, positive
amplification; 2, no amplification signal; 1/2, weak amplification signal.
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lesions where EBNA2 transcription was detected. Thus,
a potential initial event in HLP may be virus binding to
CD21, followed by viral entry and internalization of CD21.
This could result in a low level of Wp activity. The acti-
vation of Wp and expression of EBNA2 would activate
CD21 expression (Wang et al., 1990; Sugano et al., 1997).
The reexpression of CD21 in some cells with subsequent
binding of infectious virus would result in high levels of
Wp activity and also would facilitate superinfection with
other EBV strains (Sugano et al., 1997) (Fig. 6).
One of the unique features of HLP is the presence of
intertypic recombinant viral DNA (Walling and Raab-
Traub, 1994). Intertypic viral recombinant strains have
recently been isolated from HIV-negative individuals and
patients with HIV (Burrows et al., 1996; Yao et al., 1996).
To produce intertypic recombinants, two viral strains
must enter the same cell. Expression of EBNA2 with
continuing expression of CD21 would facilitate this pro-
cess. It is possible that superinfection may also be a
contributing factor to the pathogenesis of HLP. In cell
cultures, superinfection of latently infected cells with
P3HR1 virus activates viral replication while superinfec-
tion with Akata virus can activate lytic replication and can
initiate expression of latent gene products (Rabson et al.,
1982; Evans et al., 1996). Thus, the abundant virus pro-
duced in HLP could contribute to activation of latent
promoters, subsequent expression of latent gene prod-
ucts, and expression of CD21. The superinfecting EBV
could then promote lytic infection leading to the overt
viral replication that is characteristic of HLP.
MATERIALS AND METHODS
Patients and tissues
Biopsy specimens of oral hairy leukoplakia were ob-
tained from HIV-seropositive patients identified in the
University of North Carolina (UNC) Hospitals Infectious
Disease Clinic or Hospital Dental Clinic or the University
of Florida, Gainesville. Lesions were diagnosed indepen-
dently by at least two clinicians. Patients with a history of
oral candidiasis were placed on antifungal therapy for a
minimum of 14 days prior to surgical biopsy. Specimens
were immediately frozen and stored at 280°C. A portion
of each biopsy was fixed in Formalin and sent to UNC
Hospitals Department of Pathology, for hematoxylin and
eosin staining and light microscopic diagnosis. The
presence of EBV within the HLP biopsies and confirma-
tion of lytic infection were determined by identification of
the terminal repeat region by Southern blot analysis
(Raab-Traub and Flynn, 1986).
Cell lines
To compare EBV transcription in HLP with known pat-
terns of transcription, several EBV lymphoblastoid cell
lines and the C15 NPC tumor were used as positive
controls. EBV infection in Akata, a Burkitt’s lymphoma
cell line, represents type 1 latency. EBV replication can
be can be induced in Akata cells by treatment with of
anti-IgG for analysis of viral expression during permis-
sive infection in B cells (Takada, 1984). Induction was
confirmed by the detection of the replicative early anti-
gen, EA-D, on Western blot analysis. B95–8, a lympho-
blastoid cell line, represents type III latency with spon-
taneous virus production in approximately 5% of cells.
C15, a nude mouse passaged xenograft of an NPC tu-
mor, represents latency Type II and was used to com-
pare EBV expression in HLP with a latent epithelial
infection. The EBV-negative B lymphoma cell line, BJAB,
was used as a negative control. All cell lines were main-
tained in exponential growth in RPMI 1640 supplemented
with 10% fetal calf serum (Gibco BRL, Grand Island, NY).
FIG. 6. Infection of the tongue epithelium with EBV in HLP. Subse-
quent to virus binding to the cell, EBV and the receptor are internalized.
The transcription factor NF-kB is activated and viral promoter Wp is
turned on resulting in transcription of EBNA2. In occasional cells of the
HLP lesion, EBNA2 protein transactivates the CD21 promoter to reex-
press CD21 with subsequent viral superinfection with multiple EBV
strains.
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RNA isolation and cDNA synthesis
DNA and RNA were extracted from pulverized frozen
tissue or cells by ultracentrifugation on a 4 M guanidine
isothiocyanate–cesium chloride step gradient as previ-
ously described (Raab-Traub et al., 1983). Residual
DNA in the RNA fraction was removed by digestion with
DNaseI (Boehringer Manneheim). cDNA was synthe-
sized from 10 mg of total HLP RNA in 100 ml by priming
with oligodeoxythymidine using Superscript reverse tran-
scriptase (Gibco BRL) in the presence of 100 mM each
dATP, dCTP, dGTP, and dTTP. An identical reaction, con-
taining an equivalent amount of RNA and lacking reverse
transcriptase, was included as a negative control.
Polymerase chain reaction (PCR)
Tissues from patients, confirmed to have HLP by de-
tection of EBV DNA on Southern blots, were further
analyzed using RT-PCR amplification of cDNA. Amplifi-
cations were designed to detect specific mRNAs by
amplifying across splice junctions. The PCR product rep-
resenting correctly spliced mRNA can be distinguished
by size. Comparison with control cDNA reactions that
lacked RT distinguished PCR products representing un-
processed mRNA from contaminating genomic DNA
products. Aliquots (5 ml), representing the cDNA synthe-
sized from 0.5 mg of RNA, were used for each PCR
amplification. Therefore, the PCR reactions were repli-
cate, each containing the same amount of cDNA from the
individual patients, differing only in the primer pair used.
PCR amplifications of HLP cDNA were performed using
1 unit of Taq DNA polymerase (Boehringer Mannheim), in
a 1:10 dilution of 103 reaction buffer containing 2.5 mM
MgCl2, 200 mM each of dATP, dCTP, dTTP, and dGTP with
0.5 pM of each primer in a 20-ml reaction volume. Am-
plification proceeded for a total of 38 cycles with dena-
turation at 94°C for 1 min, annealing at 55°C for 1 min,
and extension at 72°C for 1 min. For detection of some
RNAs, a second set of amplifications was performed
using 1 ml of product from the first PCR amplification in
a 20-ml volume reaction and a second set of primers
internal to the primers used in the first set of amplifica-
tions. Amplification reaction (10 ml) was analyzed, and
PCR products were separated by agarose gel electro-
phoresis on a 1.5% gel and were transferred to supported
nitrocellulose (Micron Separations Inc., E. Westboro,
MA). Southern blots containing PCR products were hy-
bridized with 106 cpm/ml of a single-stranded internal
oligonucleotide probe, specific for each amplification.
Probes were end labeled with T4 polynucleotide kinase
(Promega, Madison, WI) and [g-32P]ATP (Amersham, Ar-
lington Heights, IL) according to manufacturers’ specifi-
cations. Hybridized filters were washed in 23 SSC with
0.1% SDS and exposed to Kodak XAR film at 280°.
Sensitivity of RT-PCR
The specificity of oligonucleotide primer probe combi-
nations listed in Table 1 was confirmed in a series of
RT-PCR assays. The relative sensitivity of each amplifi-
cation condition was determined by performing RT-PCR
on cell mixtures containing a standard number of EBV-
negative BJAB cells and 10-fold serial dilutions of EBV-
positive B95–8 cells. RNA from 2 3 106 cells from each of
the mixtures and control populations was subjected to
RT-PCR using the various primer probe combinations,
similar to previously described assays (Tierney et al.,
1994).
DNA sequencing
Specific bands generated by PCR were isolated by gel
electrophoresis and purified with the Gene Clean Kit (Bio
101, La Jolla, Ca). The DNA sequence was obtained by
the dideoxynucleotide chain termination method with a-
35S (Amersham, Arlington Heights, IL) and Sequenase
(version 2.0) enzyme (United States Biochemical, Cleve-
land, OH) using asymmetric PCR. Sequencing reaction
products were run on a 6% denaturing polyacrylamide
gel (Long Ranger, AT Biochemicals Inc., Malverne, PA)
with 25% formamide. Gels were exposed to Kodak film at
room temperature.
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